Vascular Age: The Hemodynamic Clock

The Elasticity of Life

In the “Guesswork Era,” we relied on blood pressure as the primary window into cardiovascular health. In the 2026 Consensus, we recognise static blood pressure as a lagging, incomplete signal. A blood pressure reading tells you the force of the flow. Vascular Age tells you the structural integrity of the pipes themselves — and whether they are silently stiffening years before blood pressure numbers start to move.

Healthy arteries are elastic. With each heartbeat, they expand to absorb the pressure wave and recoil to sustain perfusion — a buffering function that protects the brain, kidneys, and microvasculature from high-amplitude pressure oscillations. As arteries stiffen through calcification, collagen cross-linking, and AGE accumulation (directly driven by elevated HbA1c — see HbA1c Briefing), this buffering is progressively lost. The pressure wave travels faster, reflects earlier, arrives back at the heart during systole rather than diastole, and begins generating structural cardiac changes and microvascular damage in the organs it was designed to protect.

This process is measurable, trackable, and — critically — reversible through specific interventions. The instrument for measuring it is cfPWV.

I. The Mechanism: Pulse Wave Velocity and the Structural Story

Carotid-femoral Pulse Wave Velocity (cfPWV) is the gold-standard, non-invasive measure of aortic stiffness. The principle is direct and elegant: the stiffer the arterial wall, the faster a pressure wave travels through it. By measuring the transit time of the pulse between the carotid and femoral arteries (divided by the path length), cfPWV gives a precise, reproducible reading of central aortic stiffness — the most clinically predictive segment of the arterial tree.

The downstream consequences of elevated cfPWV operate through three primary pathways:

Cardiac Structural Remodelling: A faster returning pressure wave increases the afterload on the left ventricle during systole. The heart compensates over years with left ventricular hypertrophy — thickening of the myocardial wall — which reduces diastolic compliance, elevates filling pressures, and is a primary driver of heart failure with preserved ejection fraction (HFpEF).
The Brain-Kidney Exposure Problem: The brain and kidneys are high-flow, low-resistance vascular beds that normally receive a dampened, smoothed perfusion signal. When central arterial stiffness increases, the protective dampening is lost and these organs are exposed to high-amplitude pressure pulsatility — driving cerebral small vessel disease, white matter hyperintensities, hippocampal atrophy, glomerular damage, and the gradual renal filtration decline tracked by Cystatin C (see Cystatin C Briefing).
Endothelial Dysfunction: Healthy arterial endothelium produces Nitric Oxide (NO) via eNOS to maintain vasodilation and resist plaque formation. Elevated shear stress from stiffened, non-compliant walls impairs eNOS activity, reduces NO bioavailability, promotes oxidative stress, and accelerates the atherogenic process — directly linking Vascular Age to the ApoB particle retention mechanism (see ApoB Briefing).

Forge Note: cfPWV and blood pressure are related but distinct signals. Blood pressure captures the magnitude of force; cfPWV captures the structural capacity of the vessels to manage that force. An individual with well-controlled blood pressure can have significantly elevated cfPWV — and carry substantially elevated cardiovascular and cognitive risk that their BP reading entirely misses. This is the measurement gap that Vascular Age testing closes.

II. The Cognitive Connection: Stiff Arteries, Aging Brains

The PWV-cognition relationship is one of the strongest structural links in the longevity literature and one of the least communicated to the general public. The Whitehall II longitudinal cohort (Brunner et al., European Journal of Epidemiology, 2019, n=4,300, three repeated cognitive assessments over 7 years) found that individuals in the highest PWV tertile (>8.91 m/s) showed significantly accelerated decline in global cognitive score and executive function compared to the lowest tertile (<7.41 m/s) — with the association independent of age, sex, blood pressure, cardiovascular risk factors, and lifestyle variables.

The Alvarez-Bueno meta-analysis (JAHA, 2020) synthesised the cross-sectional and longitudinal evidence across multiple cohorts and confirmed a consistent negative association between arterial stiffness (PWV) and global cognition, memory, and executive function — with the longitudinal studies supporting a causal direction from stiffness to cognitive decline.

The mechanistic pathway is dual: high pulsatility damages cerebral microvasculature (white matter hyperintensities, lacunar infarcts) and impairs cerebral autoregulation — reducing the brain’s ability to maintain stable perfusion under varying systemic pressure conditions. This connects Vascular Age directly to the Deep Sleep % and HRV Trends articles: compromised cerebrovascular perfusion impairs glymphatic clearance during SWS and disrupts autonomic cardiovascular regulation.

III. The Forge Range: Age-Stratified, Not a Single Threshold

Arterial stiffness increases with age in all healthy populations — cfPWV rises approximately 0.1 m/s per year in middle-aged adults, accelerating after 60. Any clinically meaningful target must account for this. The ESC expert consensus (Laurent et al., European Heart Journal, 2006) established >10 m/s as the high-risk clinical threshold for cfPWV. The Whitehall II tertile data provides a more granular population reference for a midlife longevity-optimisation context.

Forge Editorial Note: The cfPWV Forge targets below are derived from Whitehall II (mean age 65) tertile data and supplemented with normative reference values from the Reference Values for Arterial Stiffness Collaboration (n=17,084). The <6.5 m/s target from the original article was the approximate 5th population percentile for adults over 35 — not an achievable optimisation target for most adults, and not referenced to any longevity outcome data. The revised targets reflect realistic percentile-based goals.

Age Group	ESC High-Risk Threshold	Population Median (Estimated)	Forge Optimal Target (≈25th Percentile)
30–40	> 10 m/s	~6.5–7.0 m/s	< 6.5 m/s
40–50	> 10 m/s	~7.0–7.8 m/s	< 7.0 m/s
50–60	> 10 m/s	~7.8–8.5 m/s	< 7.5 m/s
60+	> 10 m/s	~8.5–9.5 m/s	< 8.5 m/s

Pulse Pressure as the accessible proxy: Pulse pressure (systolic minus diastolic BP) is a practical home-based surrogate for central arterial stiffness. As aorta compliance falls, the pulse pressure widens. A resting pulse pressure above 50 mmHg is associated with meaningfully elevated cardiovascular risk. The 30–45 mmHg Forge target is evidence-consistent — but note that pulse pressure is a crude proxy for cfPWV and cannot substitute for direct measurement in clinical risk stratification.

Forge Verdict: If your cfPWV exceeds the population median for your age, you have measurable, actionable evidence of accelerated vascular aging — independent of whether your blood pressure reads as normal. This is the gap that defines Vascular Age testing: not what your BP is today, but how fast your arterial walls are aging relative to your chronological clock.

IV. A Note on Consumer Devices

The original article listed the Withings Body Scan and Oura Ring as home-based PWV tracking tools. This requires important qualification. The Withings Body Scan uses oscillometric cuff-based PWV — and Drager et al. (PMID 31132952) found that this measurement method’s correlation with cfPWV was only r=0.58, falling to r=0.11 after controlling for age and systolic blood pressure — meaning virtually all of the correlation was driven by those two variables, not independent arterial stiffness. The Oura Ring does not measure PWV in any validated form. These devices may provide directional data but are not substitutes for clinical cfPWV measurement.

The practical path to accurate testing:

Gold standard: cfPWV via applanation tonometry (SphygmoCor, Complior) — available at specialist clinics and some academic medical centres. A one-off annual or biennial measurement provides the most reliable Vascular Age data point.
Accessible proxy: Estimated PWV (ePWV) can be calculated from age and mean blood pressure alone using validated equations (Greve et al. formula) — free, requires no equipment, and has demonstrated association with cardiovascular outcomes in the Health and Retirement Study (n=9,293, 10–12 year follow-up, Heffernan et al., Innovation in Aging, 2022).
Daily readout: Pulse pressure (home BP cuff) provides a trending indicator — a widening pulse pressure across months to years is a real-time signal of advancing vascular stiffness.

V. The Forge Protocol: Hemodynamic Reset

Arterial stiffness is not a permanent sentence. It is one of the most modifiable structural biomarkers in the Consensus 14 — with a well-characterised, high-quality intervention evidence base.

01. Aerobic Exercise — The Primary and Best-Evidenced Lever

The Bakali et al. meta-analysis (Open Heart, 2023, 79 studies, n=3,729, including 21 RCTs) confirmed that supervised aerobic exercise training reduces PWV by a mean −0.63 m/s (95% CI −0.82 to −0.44, p<0.0001) over an average intervention duration of 11 weeks. Critically, the effect is dose-dependent and baseline-dependent: in participants with PWV ≥8 m/s, the effect size doubles to approximately −1.0 m/s — meaning those with elevated vascular age benefit most. The Ashor et al. RCT meta-analysis (PLoS One, 2014, 42 RCTs, n=1,627) confirmed aerobic exercise improves both PWV (WMD −0.63 m/s) and Augmentation Index (WMD −2.63%) significantly, while resistance training alone showed no significant effect on PWV.

The exercise specificity finding is important: A 2025 network meta-analysis (Frontiers in Cardiovascular Medicine, 43 RCTs, n=2,034) found that combined training and interval training produced the largest PWV reductions in high-risk CVD populations — larger than continuous moderate-intensity aerobic exercise alone. The Forge protocol recommendation: Zone 2 aerobic base (3–4 sessions/week) provides the primary volume stimulus; supplementing with 1–2 interval sessions per week optimises the arterial stiffness response, particularly in individuals with elevated baseline PWV.

02. Vitamin K2 (MK-7) — The Anti-Calcification Agent

As established in our Vitamin D/Magnesium Briefing, Vitamin K2 (MK-7) activates Matrix Gla Protein (MGP), the body’s primary inhibitor of arterial calcification. MGP must be carboxylated (activated) by K2 to function — K2 deficiency leaves MGP inactive, allowing calcium to deposit in arterial walls rather than bone matrix. The Rotterdam Study (n=4,807) found that the highest dietary menaquinone (K2) intake was associated with a 52% reduction in aortic calcification severity and a 57% reduction in aortic calcification-associated mortality. Dose: 100–200 µg MK-7 daily with fat-containing food.

03. Dietary Nitrates — The eNOS Support System

High-nitrate vegetables (rocket/arugula, beetroot, spinach) provide dietary nitrate that is converted via oral bacteria to nitrite and then to Nitric Oxide (NO) in the circulation — bypassing the endothelial eNOS pathway that is impaired in stiff, dysfunctional arteries. Acute ingestion of 300–500 mg dietary nitrate (approximately 200g beetroot or 100g rocket) produces measurable reductions in arterial stiffness and blood pressure within 1–3 hours. Chronic supplementation through dietary pattern is associated with sustained improvements in endothelial function markers. This is not a replacement for exercise-induced eNOS upregulation — it is an additive substrate provision strategy.

04. Blood Pressure Control — The Structural Co-Intervention

Hypertension accelerates arterial stiffening through mechanical wall stress, endothelial damage, and smooth muscle hypertrophy. Every 10 mmHg reduction in systolic BP is associated with a meaningful reduction in cfPWV — blood pressure control and arterial stiffness are reciprocally linked. The Forge target: resting systolic <120 mmHg for longevity optimisation (not merely the clinical treatment threshold of <140 mmHg). Home blood pressure monitoring (validated upper-arm cuff, average of multiple morning readings) is the most accurate method — clinic readings systematically overestimate by 5–20 mmHg due to white-coat effect.

VI. Actionable Resilience: The Audit

Establish a Baseline cfPWV Measurement. Request a clinical cfPWV test at a specialist cardiovascular or sports medicine clinic, or calculate your estimated PWV (ePWV) using the Greve equation: ePWV = 9.587 − 0.402×Age + 4.560×0.001×Age² + 0.001×(0.928×MBP) where MBP = diastolic + ⅓ × pulse pressure. Retest annually. A trajectory of declining PWV over 12–24 months of intervention is the outcome you are tracking, not a single absolute reading.
Monitor Pulse Pressure Daily. Subtract your diastolic from your systolic on your home BP cuff each morning. A trend of widening pulse pressure over months — even if absolute BP remains within normal range — is a real-time warning of arterial stiffening. Flag any consistent reading above 50 mmHg for clinical assessment.
Cross-Reference with HbA1c and ApoB. The three primary drivers of vascular calcification and stiffening are glycation (HbA1c → AGE accumulation), atherogenic particle retention (ApoB → plaque), and inflammatory load (hs-CRP → endothelial damage). A fully integrated Vascular Age audit addresses all three simultaneously rather than treating arterial stiffness as an isolated physical architecture problem.
Audit K2 Status Before Assuming Calcification Is Irreversible. Vascular calcification is not entirely fixed in adults. Emerging evidence from the PREVend cohort and intervention studies shows that K2 supplementation can decelerate and in some cases modestly reduce non-coronary calcification load. If cfPWV is elevated above the Forge target for your age bracket, addressing K2 status alongside exercise and blood pressure control is the evidence-grounded triple intervention.
Do Not Rely on Consumer Wearables for Serial PWV Tracking. Oscillometric devices (Withings Body Scan) and ring-based photoplethysmography (Oura) do not provide validated cfPWV measurements. Their correlation with true arterial stiffness, after controlling for age and blood pressure, is near-zero in validation studies. Use ePWV calculated from accurate home BP readings as the accessible proxy, not device-reported stiffness indices.

References

Vlachopoulos C. et al., JACC (2010): “Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis.” Pooled dOR cfPWV for CV mortality=11.23 (95% CI 7.29–17.29); all-cause mortality=6.52 (95% CI 4.03–10.55). AUC 0.75–0.78. DOI: 10.1016/j.jacc.2009.10.061
Brunner E.J. et al., European Journal of Epidemiology (2019): “Association of aortic stiffness with cognitive decline: Whitehall II longitudinal cohort study.” n=4,300, 3 assessments over 7 years. Highest PWV tertile (>8.91 m/s) vs. lowest (<7.41 m/s): significantly faster global cognitive score and executive function decline (P<0.01). DOI: 10.1007/s10654-019-00586-3
Alvarez-Bueno C. et al., Journal of the American Heart Association (2020): “Arterial Stiffness and Cognition Among Adults: A Systematic Review and Meta-Analysis of Observational and Longitudinal Studies.” Consistent negative association between PWV and global cognition, memory, executive function; supported by longitudinal analysis. DOI: 10.1161/JAHA.119.014621
Bakali M. et al., Open Heart (2023): “Effect of aerobic exercise training on pulse wave velocity in adults with and without long-term conditions: systematic review and meta-analysis.” 79 studies (n=3,729, 21 RCTs): mean PWV reduction −0.63 m/s (95% CI −0.82 to −0.44, p<0.0001). DOI: 10.1136/openhrt-2023-002384
Ashor A.W. et al., PLoS One (2014): “Effects of Exercise Modalities on Arterial Stiffness and Wave Reflection: A Systematic Review and Meta-Analysis of RCTs.” 42 RCTs, n=1,627. Aerobic: PWV WMD −0.63 m/s, AIx WMD −2.63%. Resistance exercise: no significant PWV effect. Higher intensity and baseline stiffness enhance aerobic effect. DOI: 10.1371/journal.pone.0110034
Laurent S. et al., European Heart Journal (2006): “Expert consensus document on arterial stiffness: methodological issues and clinical applications.” ESC high-risk cfPWV threshold >10 m/s; normative reference framework. DOI: 10.1093/eurheartj/ehl254
Heffernan K.S. et al., Innovation in Aging (2022): “Estimated Pulse Wave Velocity and All-Cause Mortality: Findings from the Health and Retirement Study.” n=9,293, 10–12 year follow-up. ePWV derived from age + MBP associated with all-cause mortality independent of CVD risk factors. DOI: 10.1093/geroni/igac056
Drager L.F. et al., American Journal of Hypertension (2019): Oscillometric PWV (Mobil-O-Graph) vs. cfPWV: correlation r=0.58, reduced to r=0.11 after controlling for age and SBP. Oscillometric devices’ PWV largely captures age and blood pressure, not independent arterial stiffness. DOI: 10.1093/ajh/hpz051
Geleijnse J.M. et al., Rotterdam Study (2004): High dietary menaquinone (K2) intake associated with 52% lower aortic calcification severity and 57% lower aortic calcification-associated mortality. DOI: 10.1093/jn/134.11.3100
Consensus 14 Metadata: “Vascular Age (cfPWV) trajectory as Physical Architecture anchor — bidirectional links with HbA1c (AGE accumulation), ApoB (plaque formation), Cystatin C (renal pulsatility damage), and DunedinPACE velocity.”